Acta Dermatovenerologica Alpina Pannonica et Adriatica最新文献_第5页

Association of HLA class II gene polymorphisms and expression levels of ORAI1/STIM1 genes in HIV-1‒positive patients with HIV-related dermatoses in Latvia. 拉脱维亚艾滋病毒相关皮肤病的 HIV-1 阳性患者中 HLA II 类基因多态性与 ORAI1/STIM1 基因表达水平的关联。

IF 0.6

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-06-01

Alena Soha, Inga Azina, Darja Arina Miskina, Viktorija Murasko, Maksims Zolovs, Andris Rubins

{"title":"Association of HLA class II gene polymorphisms and expression levels of ORAI1/STIM1 genes in HIV-1‒positive patients with HIV-related dermatoses in Latvia.","authors":"Alena Soha, Inga Azina, Darja Arina Miskina, Viktorija Murasko, Maksims Zolovs, Andris Rubins","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: This study explores the immunogenetic associations of human leukocyte antigens (HLA) and the calcium release-activated calcium modulator 1 (ORAI1) and stromal interaction molecule 1 (STIM1) genes in HIV-1‒positive patients with HIV-related skin disorders.Methods: This study assessed the distribution of variants of HLA class II alleles and expression levels of ORAI1 and STIM1 genes in the blood between HIV-1‒positive patients with HIV-related skin disorders and the control group with no HIV within the Latvian population.Results: The research group comprised 115 HIV-1‒positive patients with HIV-related skin disorders, and the control group included 80 healthy individuals. Risk alleles (HLA- DQB1*02:01-0301 and HLA-DQA1*01:01-0501) and protective alleles (HLA-DRB1*07-13, DRB1*01-13, DRB1*04-11, and HLA-DQA1*05:01-0501) showed statistical significance in the groups. In 38 out of 115 patients, higher expression levels of ORAI1 and STIM1 genes were detected in the blood at the beginning of treatment. A significantly higher level of the microribonucleic acid (mRNA) ORAI1 gene was also found in the control group.Conclusions: The results demonstrate that HLA class II alleles are associated with a trend toward risk/protection concerning HIV-related skin disorders in HIV-1‒positive patients. It was also shown that a low level of ORAI1 mRNA and the risk allele HLA-DQB1*0201-0301 were simultaneously present in the research group.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 2","pages":"89-94"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does dermatoradiology exist? 皮肤放射学存在吗？

IF 0.6

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-06-01

Corrado Tagliati, Giulio Rizzetto, Elisa Molinelli, Edoardo De Simoni, Marco Fogante, Giulia Argalia, Giuseppe Lanni, Alberto Rebonato, Luca Burroni, Gian Marco Giuseppetti, Giulio Argalia, Annamaria Offidani, Oriana Simonetti

引用次数: 0

Remission of chronic urticaria in patients treated with omalizumab. 使用奥马珠单抗治疗的慢性荨麻疹患者病情缓解。

IF 0.6

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-06-01

Klara Cvenkel, Mojca Bizjak, Julij Šelb, Mitja Košnik

{"title":"Remission of chronic urticaria in patients treated with omalizumab.","authors":"Klara Cvenkel, Mojca Bizjak, Julij Šelb, Mitja Košnik","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: This study examined the remission probability and duration in chronic spontaneous urticaria (CSU) patients resistant to second-generation H1-antihistamines (sgAHs) undergoing omalizumab treatment.Methods: This is a retrospective observational study of 176 adult CSU patients exhibiting a significant pruritus component (≥ 8) of the weekly urticaria activity score (UAS7) despite four daily sgAH tablets and starting omalizumab treatment with 300 mg every 4 weeks. After excluding 13 nonresponders, we analyzed 163 omalizumab responders (mean age 51.8 years, 74.4% female). The intervals between applications were increased. Discontinuation was considered for patients that remained asymptomatic on a gradually reduced dosage (to 150 mg every 12 weeks) without sgAHs.Results: Omalizumab discontinuation was possible in 25.8% (42/163). The duration of omalizumab treatment before remission ranged from 7 to 63 months. Twenty-one patients (50.0%) maintained complete remission until the end of the observation period (September 2021) for 8 to 68 months. Of the relapsed patients, 71.4% (15/21) effectively controlled CSU with sgAHs. Six patients (28.6%; 6/21) required omalizumab reintroduction after 6 to 40 months of remission, responding favorably.Conclusions: The study shows that a quarter of severe CSU patients achieve long-term remission. In addition, sgAHs effectively manage symptoms in a majority of relapsed cases, and those requiring omalizumab reintroduction respond favorably.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 2","pages":"59-61"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatomyositis: nailfold capillaroscopy patterns and a general survey. 皮肌炎：甲皱毛细血管镜检查模式和总体调查。

IF 0.6

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-06-01

Giusto Trevisan, Serena Bonin, Sandro Tucci, Salvino Bilancini

{"title":"Dermatomyositis: nailfold capillaroscopy patterns and a general survey.","authors":"Giusto Trevisan, Serena Bonin, Sandro Tucci, Salvino Bilancini","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Dermatomyositis (DM) is a group of autoimmune idiopathic inflammatory myopathies characterized by typical cutaneous signs and symptoms of muscle involvement. The diseases can be associated with cancer in the paraneoplastic syndrome, calcinosis, interstitial lung disease, other autoimmune connective tissue diseases (in overlap syndrome), and Raynaud's phenomenon.Methods: Clinical and capillaroscopic data were gathered from 43 patients with DM. The diagnosis was based on the Bohan‒Peter and European League against Rheumatism / American College of Rheumatology (EULAR/ACR) classification criteria. In addition, nailfold capillaroscopy was performed in all patients.Results: In our cohort, eight patients had overlap syndrome, six had paraneoplastic syndrome, eight presented with interstitial lung disease, and nine had calcinosis, two of whom also had a cancerous pathology. Raynaud's phenomenon was reported in 74% of patients. Upon nailfold capillaroscopy, 84% of patients presented giant capillaries, 81% ramified capillaries, and 70% both. The latter, notably giant ramified capillaries, could be considered specific for DM. The detection of prominent subpapillary venous plexuses was associated with pulmonary involvement. In contrast, alterations of the pericapillary spaces were associated with the severity and prognosis of DM.Conclusions: Our results underline the usefulness of nailfold capillaroscopy in the diagnosis and prognosis of DM. Based on the results and literature data, specific nailfold capillaroscopy features should be included in DM diagnostic criteria.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 2","pages":"69-79"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial. 3% 氨甲环酸乳膏与 4% 氢醌乳膏治疗有色人种混合型黄褐斑的有效性和安全性：双盲、分面随机对照试验。

IF 0.6

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-06-01

Nevi Yasnova, Sondang P Sirait, Githa Rahmayunita

{"title":"The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.","authors":"Nevi Yasnova, Sondang P Sirait, Githa Rahmayunita","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Melasma, a chronic acquired skin pigmentation disorder, is characterized by the presence of irregular-edged brown to gray-brown patches with a symmetrical distribution, primarily on sun-exposed areas such as the face. Topical hydroquinone (HQ) is the gold standard for melasma treatment but has numerous side effects. This study assesses the effectiveness of topical tranexamic acid (TA) as an alternative for melasma treatment.Methods: In a double-blind, split-face, randomized controlled trial involving 20 subjects, the effectiveness of 3% TA versus 4% HQ cream was evaluated over 8 weeks. The modified melasma area and severity index (mMASI), melanin index, erythema index, and side effects were assessed. Subjective improvement was measured using the patient global assessment (PtGA).Results: A significant decline in the mMASI score was observed at weeks 4 and 8 in both groups compared to baseline. There were no statistically significant differences in PtGA scores between the 3% TA group and the 4% HQ group.Conclusions: Topical 3% TA is as effective and safe as 4% HQ for treating melasma in the Indonesian population, with potential advantages in terms of side-effect profiles.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 2","pages":"83-88"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Photoaging assessment by Glogau classification: correlation of dermoscopy findings in the coastal population of Indonesia. 用 Glogau 分类法评估光老化：印度尼西亚沿海居民皮肤镜检查结果的相关性。

IF 1.2

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-03-01

Putu Martha Gerynda Sukma, Sri Linuwih Sw Menaldi, Larisa Paramitha Wibawa, Shannaz Nadia Yusharyahya, Marsen Isbayuputra

{"title":"Photoaging assessment by Glogau classification: correlation of dermoscopy findings in the coastal population of Indonesia.","authors":"Putu Martha Gerynda Sukma, Sri Linuwih Sw Menaldi, Larisa Paramitha Wibawa, Shannaz Nadia Yusharyahya, Marsen Isbayuputra","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: To date, there is no gold standard for identifying photoaging. This study investigates the correlation of photoaging profiles based on the Glogau scale and the dermoscopy photoaging scale (DPAS) in a coastal population.Methods: An analytical cross-sectional study was conducted at Cilincing Municipal Health Center in Jakarta in October 2022. Individuals living in the coastal area, 20 years and older, with Fitzpatrick skin types III-V, and with a mean daily sun exposure of ≥ 3 hours were included. The Glogau scale and DPAS were assessed through history taking, physical examination, and dermoscopic examination. A Spearman correlation test was used to assess the correlation between the Glogau scale and DPAS.Results: Thirty individuals with a mean age of 41.5 ± 11.5 years participated in the study. The median Glogau score was 3 (range: 2-4). The mean DPAS score was 28.5 ± 5.6. Lentigo, hypo-hyperpigmented macules, telangiectasia, deep wrinkles, and superficial wrinkles were observed in all subjects. There was a moderate positive correlation between the Glogau scale and DPAS (r = 0.536, p = 0.002).Conclusions: The Glogau scale has a significant correlation with DPAS. DPAS can serve as a reliable, easy, practical, and fast diagnostic tool to assess the severity of aging.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 1","pages":"1-5"},"PeriodicalIF":1.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of plaque-psoriasis in HIV-positive patients. 治疗艾滋病毒阳性患者的斑块状银屑病。

IF 1.2

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-03-01

Vita Jugovac, Marija Gulin, Dora Barić, Daniela Ledić Drvar, Romana Čeović

{"title":"Treatment of plaque-psoriasis in HIV-positive patients.","authors":"Vita Jugovac, Marija Gulin, Dora Barić, Daniela Ledić Drvar, Romana Čeović","doi":"","DOIUrl":"","url":null,"abstract":"Psoriasis is a chronic inflammatory disease that can often accompany human immunodeficiency virus (HIV) epidemics. Development of psoriasis in HIV patients is correlated with a decrease in CD4+ count. Significant variability in the clinical presentation of psoriasis makes it a challenging disease to diagnose. Furthermore, associated immunodeficiency complicates standard treatment with immunosuppressive and biological therapy. Articles that match the terms psoriasis and HIV were searched in MEDLINE and Embase and selected based on their relevance. Highly active antiretroviral therapy (HAART) is a medication regimen used to manage and treat HIV infection. In treating mild psoriasis in HIV-positive patients, topical agents combined with HAART are considered first-line therapy, followed by phototherapy. Second-line therapy includes oral retinoids, alone or combined. In treating challenging cases, apremilast has been used due to its lack of immunosuppressive effect. In case of progressive and refractory disease, limited data from studies suggest that immunosuppressive or biological therapy may be effective. Treatment of psoriasis in HIV patients remains a challenge, which is largely attributable to its complicated etiopathology and lack of an approved therapy option. In treating severe psoriasis, close collaboration with an infectious disease specialist is highly recommended. Further research is needed, preferably with an aim toward developing individualized therapy.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 1","pages":"37-40"},"PeriodicalIF":1.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digging into uncertainty: a case report on Spitz lesions. 挖掘不确定因素：关于斯皮茨病变的病例报告。

IF 1.2

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-03-01

Eva Klara Merzel Šabović, Dragan Jejinić, Andreja Pagon, Nina Jugovar, Violeta Hosta

引用次数: 0

Review of virological methods for laboratory diagnosis and characterization of monkeypox virus (MPXV): lessons learned from the 2022 Mpox outbreak. 猴痘病毒（MPXV）实验室诊断和定性的病毒学方法回顾：从 2022 年猴痘爆发中吸取的经验教训。

IF 1.2

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-03-01

Katarina Resman Rus, Samo Zakotnik, Martin Sagadin, Marko Kolenc, Lucijan Skubic, Nataša Knap, Misa Korva, Mario Poljak, Tatjana Avšič-Županc

{"title":"Review of virological methods for laboratory diagnosis and characterization of monkeypox virus (MPXV): lessons learned from the 2022 Mpox outbreak.","authors":"Katarina Resman Rus, Samo Zakotnik, Martin Sagadin, Marko Kolenc, Lucijan Skubic, Nataša Knap, Misa Korva, Mario Poljak, Tatjana Avšič-Županc","doi":"","DOIUrl":"","url":null,"abstract":"Monkeypox virus (MPXV), originally endemic in West Africa (Clade II) and Central Africa (Clade I), has recently emerged worldwide and has reinforced the need for rapid and accurate MPXV diagnostics. This review presents and critically discusses the range of virological methods for laboratory diagnosis and characterization of MPXV as well as related lessons learned and practical experience gained from the 2022 Mpox global outbreak. Real-time PCR is currently considered the diagnostic gold standard and ensures accurate and timely confirmation of suspected Mpox cases based on suspicious skin lesions, and digital PCR improves the precision of MPXV DNA quantification. Whole genome sequencing reveals the diversity within the Clade IIb outbreak and highlights the role of microevolution in the adaptation of the virus to the human host. Continuous genomic surveillance is important for better understanding of human-to-human transmission and prevention of the emergence of variola virus-like strains. Traditional virological methods such as electron microscopy and virus isolation remain essential for comprehensive virus characterization, particularly in the context of vaccine and antiviral drug development. Despite the current challenges, serological tests detecting a range of anti-MPXV antibodies are important adjunct diagnostic and research tools for confirmation of late-presenting or asymptomatic MPXV cases, contact tracing, epidemiological studies, seroepidemiological surveys, and better understanding of the role of IgG and neutralizing antibodies in the immune response to infection and vaccination. A multidisciplinary approach combining advanced molecular techniques with traditional virological methods is important for rapid and reliable diagnosis, surveillance, and control of the outbreak.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 1","pages":"23-35"},"PeriodicalIF":1.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139098927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 and oral lesions: 2020-2024 outpatient case series and literature review. COVID-19 与口腔病变：2020-2024 年门诊病例系列和文献综述。

IF 1.2

Acta Dermatovenerologica Alpina Pannonica et Adriatica Pub Date : 2024-03-01

Ana Glavina, Jozo Badrov, Marino Lukenda, Karmela Džaja, Dolores Biočina-Lukenda, Liborija Lugović-Mihić

{"title":"COVID-19 and oral lesions: 2020-2024 outpatient case series and literature review.","authors":"Ana Glavina, Jozo Badrov, Marino Lukenda, Karmela Džaja, Dolores Biočina-Lukenda, Liborija Lugović-Mihić","doi":"","DOIUrl":"","url":null,"abstract":"Data on oral lesions of coronavirus disease (COVID-19) are conflicting, and there are few evidence-based data on oral lesions directly caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this case series and literature review is to determine the prevalence of oral lesions associated with COVID-19 in outpatients and identify oral manifestations that are likely associated with COVID-19. We present 15 patients that came for their first specialist examination to the Oral Medicine Outpatient Clinic, Dental Clinic, Split, Croatia between November 2020 and January 2024. Their medical and dental history was taken following CARE guidelines. The prevalence of oral lesions associated with SARS-CoV-2 was 1.42% during the 4-year follow-up period. The most common oral lesions were nonspecific erosions, stomatitis, salivary flow disorders (xerostomia, oligosialia), salivary gland diseases (sialadenitis, chronic sialadenitis), candidiasis, pigmentation, aphthae, burning mouth syndrome, and geographic and fissured tongue. The mean latency period was 25.1 days. The site most commonly affected was the tongue (61.5%). Oral lesions associated with COVID-19 occurred in middle-aged patients, with an equal distribution by sex. They presented in a mild form and did not correlate with the severity of the clinical picture of COVID-19.","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"33 1","pages":"41-48"},"PeriodicalIF":1.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0